Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 29.24.
Forward PE Ratio (29.24) = Close Price ($548.05) / Consensus Forward EPS ($18.74)
FORWARD PE RATIO
29.24
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
+46.82%
vs the sector median at left
Vertex Pharmaceuticals Incorporated
Market Cap
$139.10B
Forward PE Ratio
29.24
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | $139.10B | 29.24 |
| Bristol-Myers Squibb Company (BMY)vs › | $136.88B | 9.67 |
| Intuitive Surgical, Inc. (ISRG)vs › | $133.83B | 35.08 |
| Stryker Corporation (SYK)vs › | $126.30B | 21.93 |
| Danaher Corporation (DHR)vs › | $153.85B | 25.74 |
| Medtronic plc (MDT)vs › | $119.49B | 16.92 |
| CVS Health Corp. (CVS)vs › | $118.69B | 11.66 |
| Pfizer Inc. (PFE)vs › | $159.98B | 9.44 |
| GSK plc (GSK)vs › | $105.00B | 14.65 |
| McKesson Corporation (MCK)vs › | $100.56B | 22.02 |
Trailing P/E
31.9
reported TTM EPS
Forward P/E
29.2
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $18.74 implies +9.1% EPS growth vs the reported trailing $17.18.
At today's $548.05 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $18.74 | $18.14 – $19.13 | 10 | 29.2x |
| 2027-12-31 | $21.40 | $18.70 – $23.02 | 11 | 25.6x |
| 2028-12-31 | $25.49 | $19.57 – $32.70 | 7 | 21.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute